Compare SGRP & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | ELUT |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 25.2M |
| IPO Year | 1996 | 2020 |
| Metric | SGRP | ELUT |
|---|---|---|
| Price | $0.86 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 67.6K | ★ 252.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,130,000.00 | $21,746,000.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.79 | ★ 24.08 |
| 52 Week Low | $0.85 | $0.58 |
| 52 Week High | $2.10 | $4.84 |
| Indicator | SGRP | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 45.00 |
| Support Level | $0.85 | $0.66 |
| Resistance Level | $0.92 | $0.72 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 6.67 | 54.78 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.